MRTX849
Phase 3Small molecule
MRTX849 is one of 95 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
3
Indications
10
Total Trials
4
Active Trials
94
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Yervoy
Bristol-Myers SquibbPreclinical
MRTX849
MMirati Therapeutics Inc.
Phase 3
Gemzar
GGynecologic Oncology Group
Preclinical
Lenvima
EisaiPreclinical
Vizimpro
PfizerPreclinical
Ofev
Boehringer IngelheimPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Patients With Advanced Solid Tumors2 trials
Cancer2 trials
Non-Small Cell Lung Cancer2 trials
Pancreatic Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MRTX849. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMirati Therapeutics Inc.